StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Primaxin (imipenem and cilastatin, legacy) by Quarter

Primaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Primaxin (imipenem and cilastatin, legacy): $39M in Q4 2023, down 27.8% from a year earlier. That is the lowest of the 32 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2023
39
Period ended Dec 31, 2023
Change on a year earlier
-27.8%
54 in Q4 2022
History
32 quarters
Since Q1 2016
Sources
7
Documents cited below

Where the Q4 2023 figure comes from

“|| Primaxin | 80 | 53 | 41 | 39 | 213 | 58 | 64 | 63 | 54 | 239 | -28 | -28 | -11 | -6”

Source: Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrimaxin (imipenem and cilastatin, legacy) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202339-27.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202341-34.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q2 2023Jun 30, 202353-17.2%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q1 2023Mar 31, 202380+37.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q4 2022Dec 31, 202254-16.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202263-10.0%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q2 2022Jun 30, 202264+6.7%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q1 2022Mar 31, 202258-10.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q4 2021Dec 31, 202165+4.8%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q3 2021Sep 30, 202170-5.4%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202160-6.2%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2021Mar 31, 202165+27.5%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q4 2020Dec 31, 202062-7.5%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2020Sep 30, 202074-3.9%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q2 2020Jun 30, 202064-9.9%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q1 2020Mar 31, 202051-13.6%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗

Breakdown

What makes up primaxin (imipenem and cilastatin, legacy)

Cite this data

StockData. (2026). Merck Primaxin (imipenem and cilastatin, legacy) ($M), quarterly Q1 2016–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-primaxin

See every metric in the Merck KPI table. Data updated Oct 26, 2026.